Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case

  • Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit
  • Ruling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases
  • Sandoz remains deeply committed to providing Erelzi® as soon as possible, contributing to a more sustainable healthcare system

Holzkirchen, Germany, 9 August 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States …

/by

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case

  • Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit
  • Ruling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases
  • Sandoz remains deeply committed to providing Erelzi® as soon as possible, contributing to a more sustainable healthcare system

Holzkirchen, Germany, 9 August 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States …

/by

Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis

  • Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1] 
  • Osteoporosis accounts for 8.9m bone fractures annually, including debilitating hip fractures — number set to increase substantially over next two decades[2]
  • Sandoz has eight marketed biosimilar medicines globally and 10+ molecules in the pipeline including proposed biosimilar denosumab

Holzkirchen, July 22, 2019 – Sandoz, a Novartis division and a global leader in …

/by

Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased

  • Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by:
    • Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%)
    • Entresto grew to USD 421 million, +81% (cc) with increased initiation in hospital and ambulatory settings
    • Oncology sales grew 9% (cc) driven by growth from Lutathera (USD 109 million), Kisqali (USD 111 million) and Kymriah (USD 58 million) in the second quarter
    • Sandoz sales grew 3% (cc, -1% USD) as ex-US growth more than …
/by

Sandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine

  • Adult and pediatric doses immediately available as single-dose, pre-filled syringe and device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis1
  • SYMJEPI will help address critical impact of ongoing epinephrine auto-injector shortages2 for the one in 50 Americans at risk for anaphylaxis3
  • Sandoz is committed to helping people access high quality healthcare at affordable prices, with strong focus on areas of unmet patient need

Princeton, New …

/by

Sandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicine

  • Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1]
  • More than 300,000 European men and women are diagnosed with lung cancer annually, making it the fourth most common cancer[2]
  • With launch Sandoz builds on robust 50+ medicine oncology portfolio globally, including chemotherapy, targeted therapy, hormones and supportive care[3]

Holzkirchen, Germany, July 2, 2019 – Sandoz today announced the launch of the generic …

/by

Sandoz enters agreement with Kit Check to track, automate restocking of products in U.S. hospitals

  • Sandoz and Kit Check will help hospital pharmacies cut costs, reduce risk, and better support hospital staff in treating their patients safely and more efficiently
  • Collaboration will optimize supply chain by providing real-time inventory reports, plus timely tracking of recalls and expiration of products
  • Kit Check™ uses powerful machine learning and advanced tracking technology to streamline medication inventory, workflow, and auditing processes

Princeton, New Jersey, June 27, 2019 – Sandoz Inc, a Novartis …

/by

New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy

  • Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[1]
     
  • ADMYRA data reinforces review summarizing 90+ publications, that switching from reference …
/by

Sandoz announces plan to improve competitiveness and realign the organization, to drive ongoing Transformation and support future growth

  • Two-stage strategic Transformation plan foresees measures for organizational realignment, followed by increased investments to drive growth segments
  • Realignment of organization involves a planned reduction of global workforce by approximately 900 FTEs, including closure of Holzkirchen development center

HOLZKIRCHEN, May 15, 2019 – Sandoz today announces plans for a leaner and more efficient global organization, to drive cost competitiveness as the first stage of its ongoing strategic Transformation and support investments into future growth. …

/by

Sandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation system

  • Sandoz receives generic approval for Rosuvastatin from China’s National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system
  • Generic approval under China’s recently introduced QCE system is first of a kind for multinational pharmaceutical company
  • Regulatory milestone demonstrates long-term strategic focus on pioneering access to high-quality medicines in world’s largest, and rapidly-growing, generics market

Holzkirchen, Germany, May 9, 2019 – Sandoz today announced that it …

/by